Gelonghui, November 25丨3SBIO (01530.HK) announced that its subsidiary, Shenyang 3SBIO Pharmaceutical Co., Ltd., has reached a cooperation agreement with Guangdong HEC CJ PHARM and its subsidiary, Yichang HEC CJ PHARM, regarding Benzylsulfonic acid Crizotinib.
The agreement specifies that Shenyang 3SBIO will obtain exclusive commercialization rights for specific indications of Crizotinib in mainland China under Guangdong HEC CJ PHARM's product line. According to the agreement, Shenyang 3SBIO will pay Guangdong HEC CJ PHARM a down payment as well as corresponding milestone payments for research and development and sales. Guangdong HEC CJ PHARM will continue to be responsible for the research and development, registration, and production of Crizotinib.